Urinary Biomarkers Can Predict Response in Lupus Nephritis

This article originally appeared here.
Share this content:
Urinary Biomarkers Can Predict Response in Lupus Nephritis
Urinary Biomarkers Can Predict Response in Lupus Nephritis

TUESDAY, Aug. 2, 2016 (HealthDay News) -- Low abundance biomarker panels can predict lupus nephritis outcomes, according to research published online July 27 in Arthritis & Rheumatology.

Noting that the American College of Rheumatology guidelines recommend change in lupus nephritis induction therapy when no response has occurred within six months, Bethany J. Wolf, Ph.D., from the University of South Carolina in Charleston, and colleagues analyzed biomarker models to develop a tool for defining response. In 140 patients with biopsy-proven lupus nephritis who had not yet started induction therapy, the authors analyzed urine samples for a panel of urinary biomarkers. For each individual biomarker, they generated univariate receiver operating characteristic (ROC) curves, and compared them to the ROC area under the curve values from models developed using random forest algorithms.

The researchers found that there was clinically meaningful predictive power for models developed with the combined traditional and novel biomarker panels. Chemokines, cytokines, and markers of cellular damage were the most predictive of response.

"This is the first study to demonstrate the power of low-abundance biomarker panels and machine learning algorithms for predicting lupus nephritis outcomes," the authors write. "This is a critical first step in research to develop clinically meaningful decision support tools."

Subject materials were provided by Genentech and Bristol-Myers Squibb.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »